Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 3, 2014

View Archived Issues

Studies in animal model support idea of AAV-snRNA mediated exon-skipping for DMD

RaQualia presents preclinical findings on novel TRPM8 antagonists for neuropathic pain

Data and safety monitoring board recommends continuing phase III study of CPX-351

TG Therapeutics confirms start of trial of TGR-1202 with ibrutinib for B-cell malignancies

Ampio provides week 20 update on open-label portion of STRUT study of Ampion

Abeona Therapeutics raises funding to support Sanfilippo syndrome program

Unum Therapeutics initiates phase I trial of antibody-coupled T-cell receptor therapy

Homologous recombination deficiency score can predict response to niraparib in ovarian cancer

Lilly reports discovery and preclinical characterization of novel cathepsin S inhibitor

Nippon Shinyaku and Pfizer launch Tramal in Japan for cancer pain and chronic pain

Phase I results for recombinant ApoA-I Milano/phospholipid complex as treatment of atherosclerosis

Abivax completes first-in-human study of ABX-464

Actelion submits selexipag for approval in Europe

Eternity Bioscience patent details novel BRAF inhibitors

Dr August Wolff Group patent reports kappa-opioid agonists

N30 Pharmaceuticals presents novel CFTR modulators

Jiangsu Hengrui Medicine patents URAT1 inhibitors

Phase I data presented for CC-220 as treatment for SLE and other autoimmune diseases

Lung Therapeutics' LTI-01 receives FDA orphan drug designation

Pfizer acquires Baxter's marketed vaccines

Synageva BioPharma provides regulatory update for sebelipase alfa

Actinogen completes acquisition of Corticrine

Otsuka Pharmaceutical to acquire Avanir Pharmaceuticals

Momenta Pharmaceuticals to initiate clinical trial of M-923, a Humira biosimilar

EMA starts review of MAA of NPS Pharmaceuticals' Natpar

Cepheid receives FDA clearance to market norovirus diagnostic

FDA approves Xuanzhu Pharma's IND application for pirotinib

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...